Recordati Industria Chimica E Farmaceutica Q2 2026 Earnings Report

Recordati Industria Chimica E Farmaceutica EPS Results

• Actual EPS: $0.91
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Recordati Industria Chimica E Farmaceutica Revenue Results

• Actual Revenue: $810.70 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Recordati Industria Chimica E Farmaceutica Announcement Details

• Quarter: Q2 2026
• Date: 7/29/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) is an Italy-based pharmaceutical company focused on the research, development, manufacture and commercialization of prescription medicines. Its business is centered on specialty-care and rare-disease treatments, as well as selected products for primary care and other therapeutic areas.

The company’s portfolio includes medicines for conditions such as endocrine disorders, cardiovascular disease, central nervous system disorders and rare diseases. Recordati markets both proprietary products and established branded medicines, including treatments based on active ingredients such as osilodrostat, cariprazine and lercanidipine. Its rare-disease operations expanded through the acquisition of EUSA Pharma, which added products for specialized and orphan indications.

Founded in Italy in 1926 by Giovanni Recordati, the company has developed from a domestic pharmaceutical business into an international group. Recordati serves healthcare markets across Europe and in other regions, including the United States and selected countries in the Middle East, North Africa and Latin America. The group is headquartered in Milan, Italy, and is led by Chief Executive Officer Rob Koremans, with Andrea Recordati serving as chairman.